Kyle Piskel - 04 Feb 2026 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)

Signature
/s/ Kyle Piskel
Issuer symbol
ADPT
Transactions as of
04 Feb 2026
Net transactions value
-$13,556
Form type
4
Filing time
06 Feb 2026, 19:30:18 UTC
Previous filing
14 Jan 2026
Next filing
06 Mar 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
PISKEL KYLE Chief Financial Officer C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE /s/ Kyle Piskel 06 Feb 2026 0001780662

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADPT Common Stock Options Exercise $26,040 +2,145 +0.99% $12.14 218,782 04 Feb 2026 Direct F1
transaction ADPT Common Stock Sale $39,597 -2,145 -0.98% $18.46 216,637 04 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADPT Stock Option (right to buy) Options Exercise $0 -2,145 -50% $0.000000 2,146 04 Feb 2026 Common Stock 2,145 $12.14 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2025.
F2 The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.